Page last updated: 2024-10-16

adenine and Kidney Diseases

adenine has been researched along with Kidney Diseases in 200 studies

Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.

Research Excerpts

ExcerptRelevanceReference
"Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively."9.12Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. ( Arterburn, S; Borroto-Esoda, K; Brosgart, C; Chuck, S; Colombo, M; Hadziyannis, S; Lai, CL; Neuhaus, P; Samuel, D; Schiff, E; Terrault, N; Tillmann, H; Villeneuve, JP; Zeuzem, S, 2007)
"Long-term adefovir dipivoxil therapy is connected to renal dysfunction in chronic hepatitis B, necessitating the monitoring of kidney function."8.93Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis. ( Cheng, F; Deng, Y; Kang, J; Luo, Q; Zeng, W; Zhang, D; Zhong, S, 2016)
"We investigated antifibrotic effects of capsaicin in two mouse renal fibrosis models as follows: C57BL/6J mice were subjected to unilateral ureteral obstruction (UUO) and fed with an adenine-rich diet."8.12Capsaicin ameliorates renal fibrosis by inhibiting TGF-β1-Smad2/3 signaling. ( Li, X; Liu, Z; Meng, D; Tang, S; Wang, H; Wang, W; Wu, Y; Xia, W; Zhang, J; Zhou, X, 2022)
"Adefovir dipivoxil (ADV) is one of the most important nucleostide analogues currently in use for the treatment of chronic hepatitis B virus (HBV) infection."7.91Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible? ( Dai, ZJ; Jin, J; Pan, YJ; Qian, YY; Ruan, LY; Shi, MT; Wu, CM; Zhu, YX, 2019)
"Renal dysfunction and Fanconi's syndrome associated with hypophosphatemia caused by long-term administration of low-dose adefovir dipivoxil (ADV) has been reported in recent years."7.80Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. ( Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Tanaka, M, 2014)
"Chronic hepatitis B patients (CHB) treated with adefovir were followed up to evaluate nephrotoxicity and its outcome."7.79Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B. ( Aung, MO; Chiu, LL; Dan, YY; Gowans, M; Hartono, JL; Khoo, MJ; Koay, E; Lee, GH; Lee, YM; Lim, K; Lim, SG; Low, HC; Soon, C; Tan, PS; Thwin, MA, 2013)
" Treatment of chronic hepatitis C in patients coinfected with HIV is a complex problem associated with toxicities and drug interactions between HIV antiretrovirals and interferon and ribavirin."7.79Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. ( Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M, 2013)
"Tenofovir is a nucleotide reverse-transcriptase inhibitor approved for treatment of human immunodeficiency virus infection, as well as chronic hepatitis B (CHB)."7.78Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. ( Baqai, S; Clark, MD; Gish, RG; Kane, SD; Mangahas, MF; Shaw, RE, 2012)
"To study the preventive and therapeutic effects of Quercetin (Que) on hyperuricemia and renal failure in rats."7.77[Preventive and therapeutic effects of quercetin on hyperuricemia and renal injury in rats]. ( Fu, R; He, W; Yao, F; Zhang, R, 2011)
" In this study, we showed elevated HMGB1 expression in renal granulomas in rats with crystal-induced granulomatous nephritis caused by feeding an adenine-rich diet."7.76High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy. ( Biswas, KK; Hashiguchi, T; Kawahara, K; Lotz, M; Maruyama, I; Nitanda, T; Oyama, Y; Tancharoen, S; Taniguchi, N; Uchimura, T; Umekita, Y, 2010)
"Tenofovir-related tubule damage characterized by Fanconi syndrome, renal insufficiency and nephrogenic diabetes insipidus has been reported in the adult HIV-infected population."7.73Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. ( Hussain, S; Khayat, A; Rathore, MH; Tolaymat, A, 2006)
"Renal fibrosis is a common pathological feature of the progression of chronic kidney disease."5.46Valproic acid attenuates renal fibrosis through the induction of autophagy. ( Doi, S; Doi, T; Kawaoka, K; Masaki, T; Nakashima, A; Ueno, T; Yamada, K, 2017)
" Modification of the dosing interval or discontinuation of ADV was required in seven and three patients, respectively, and none of them showed a further decline in the eGFR."5.38Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. ( Cho, HC; Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2012)
"Gout is principally a disease of middle-aged men."5.26Uric acid crystal-induced nephropathy: evidence for a specific renal lesion in a gouty family. ( Cameron, JS; Dillon, MJ; Farebrother, DA; Pincott, JR; Simmons, HA; Warren, DJ, 1981)
"Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively."5.12Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. ( Arterburn, S; Borroto-Esoda, K; Brosgart, C; Chuck, S; Colombo, M; Hadziyannis, S; Lai, CL; Neuhaus, P; Samuel, D; Schiff, E; Terrault, N; Tillmann, H; Villeneuve, JP; Zeuzem, S, 2007)
"The antiviral agent tenofovir is highly effective for the treatment of HIV and hepatitis B virus infections, and the older prodrug tenofovir disoproxil fumarate (TDF) is also a component of daily preexposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk populations."4.98Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. ( Asriel, B; Chan, L; Eaton, EF; Wyatt, CM, 2018)
"Long-term adefovir dipivoxil therapy is connected to renal dysfunction in chronic hepatitis B, necessitating the monitoring of kidney function."4.93Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis. ( Cheng, F; Deng, Y; Kang, J; Luo, Q; Zeng, W; Zhang, D; Zhong, S, 2016)
"We investigated antifibrotic effects of capsaicin in two mouse renal fibrosis models as follows: C57BL/6J mice were subjected to unilateral ureteral obstruction (UUO) and fed with an adenine-rich diet."4.12Capsaicin ameliorates renal fibrosis by inhibiting TGF-β1-Smad2/3 signaling. ( Li, X; Liu, Z; Meng, D; Tang, S; Wang, H; Wang, W; Wu, Y; Xia, W; Zhang, J; Zhou, X, 2022)
" MYDGF164 alleviated capillary rarefaction, hypoxia, renal fibrosis, and tubular atrophy in UUO mice and in adenine-induced CKD rats."4.12Mucin-fused myeloid-derived growth factor (MYDGF164) exhibits a prolonged serum half-life and alleviates fibrosis in chronic kidney disease. ( Du, P; Wang, H; Wang, T; Yang, M; Yin, H, 2022)
" The efficacy of the CTGF vaccine on renal fibrosis was evaluated in adenine-induced CKD and unilateral ureteral obstruction (UUO) murine models."4.12Vaccination against connective tissue growth factor attenuates the development of renal fibrosis. ( Azegami, T; Hayashi, K; Hishikawa, A; Itoh, H; Nakamichi, R; Nakayama, T; Sugita, E; Yoshimoto, N, 2022)
"Adefovir dipivoxil (ADV) is one of the most important nucleostide analogues currently in use for the treatment of chronic hepatitis B virus (HBV) infection."3.91Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible? ( Dai, ZJ; Jin, J; Pan, YJ; Qian, YY; Ruan, LY; Shi, MT; Wu, CM; Zhu, YX, 2019)
"To investigate the predictors of proximal kidney tubular dysfunction (PKTD) induced by adefovir dipivoxil (ADV) treatment for chronic hepatitis B."3.81Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B. ( Furusyo, N; Harada, Y; Hayashi, J; Hayashi, T; Ihara, T; Ikezaki, H; Murata, M; Ogawa, E; Shimizu, M; Toyoda, K, 2015)
" MR images were acquired on two mouse models of kidney injury: adenine-induced chronic kidney disease (CKD) and rhabdomyolysis-induced acute kidney injury (AKI)."3.80Assessment with unenhanced MRI techniques of renal morphology and hemodynamic changes during acute kidney injury and chronic kidney disease in mice. ( Abramovitch, R; Axelrod, JH; Heyman, SN; Milman, Z; Nachmansson, N, 2014)
"Renal dysfunction and Fanconi's syndrome associated with hypophosphatemia caused by long-term administration of low-dose adefovir dipivoxil (ADV) has been reported in recent years."3.80Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. ( Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Tanaka, M, 2014)
" The risks associated with initiating tenofovir immediately in pregnant women before reviewing serum creatinine results may be limited, and the benefits of rapid ART initiation in pregnancy may outweigh possible risks of nephrotoxicity."3.79Low prevalence of renal dysfunction in HIV-infected pregnant women: implications for guidelines for the prevention of mother-to-child transmission of HIV. ( Bekker, LG; Kamkuemah, M; Kaplan, R; Myer, L, 2013)
" Treatment of chronic hepatitis C in patients coinfected with HIV is a complex problem associated with toxicities and drug interactions between HIV antiretrovirals and interferon and ribavirin."3.79Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. ( Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M, 2013)
"Chronic hepatitis B patients (CHB) treated with adefovir were followed up to evaluate nephrotoxicity and its outcome."3.79Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B. ( Aung, MO; Chiu, LL; Dan, YY; Gowans, M; Hartono, JL; Khoo, MJ; Koay, E; Lee, GH; Lee, YM; Lim, K; Lim, SG; Low, HC; Soon, C; Tan, PS; Thwin, MA, 2013)
"Tenofovir is a nucleotide reverse-transcriptase inhibitor approved for treatment of human immunodeficiency virus infection, as well as chronic hepatitis B (CHB)."3.78Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. ( Baqai, S; Clark, MD; Gish, RG; Kane, SD; Mangahas, MF; Shaw, RE, 2012)
"To study the preventive and therapeutic effects of Quercetin (Que) on hyperuricemia and renal failure in rats."3.77[Preventive and therapeutic effects of quercetin on hyperuricemia and renal injury in rats]. ( Fu, R; He, W; Yao, F; Zhang, R, 2011)
" In this study, we showed elevated HMGB1 expression in renal granulomas in rats with crystal-induced granulomatous nephritis caused by feeding an adenine-rich diet."3.76High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy. ( Biswas, KK; Hashiguchi, T; Kawahara, K; Lotz, M; Maruyama, I; Nitanda, T; Oyama, Y; Tancharoen, S; Taniguchi, N; Uchimura, T; Umekita, Y, 2010)
"After adenine dosing, significant hyperphosphatemia, hypocalcemia and secondary hyperparathyroidism (2HPT) were observed during the experimental period of 15 weeks."3.75Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. ( Fujimori, A; Fukushima, S; Itoh, H; Mizukami, K; Nara, H; Okada, M; Sanagi, M; Takakura, K; Terai, K, 2009)
"Tenofovir-related tubule damage characterized by Fanconi syndrome, renal insufficiency and nephrogenic diabetes insipidus has been reported in the adult HIV-infected population."3.73Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. ( Hussain, S; Khayat, A; Rathore, MH; Tolaymat, A, 2006)
"The adenine-containing diet caused renal failure, characterized by crystal deposits, cystic dilatation of tubules, and micro-abscesses."3.01Functional and histological effects of Anthurium schlechtendalii Kunth extracts on adenine-induced kidney damage of adult Wistar rats. ( Ajibola, OO; Barradas-Dermitz, DM; Calderón-Garcidueñas, AL; Carvajal-Zarrabal, O; López-Amador, N; Nolasco-Hipolito, C, 2023)
"Increased risk of lactic acidosis has also been described for those with impaired liver and renal function taking entecavir."2.50Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. ( Fung, J; Lai, CL; Seto, WK; Yuen, MF, 2014)
" Dosing antiretroviral agents with kidney metabolism should be adjusted when eGFR is bellow 50 mL/min/1."2.48[Kidney and HIV infection]. ( Lescure, FX; Plaisier, E; Ronco, P, 2012)
" Despite its proven efficacy and safety, cases of kidney tubular dysfunction have increasingly been reported and concern exists about the risk of nephrotoxicity associated with the long-term use of TFV."2.46Renal toxicity associated with tenofovir use. ( Alvarez, E; Labarga, P; Rodriguez-Nóvoa, S; Soriano, V, 2010)
" Its favorable profile in terms of high efficacy, low toxicity and once-daily dosing makes TDF one of the most attractive antiretroviral agents, and therefore, it is widely used."2.45Pharmacogenetics of tenofovir treatment. ( Labarga, P; Rodriguez-Novoa, S; Soriano, V, 2009)
" Most data on safety and efficacy in this scenario initially came from clinical trials in which tenofovir was combined with non-nucleoside reverse transcriptase inhibitors."2.44[Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors]. ( Fiorante, S; Pulido, F, 2008)
" This drug is administered orally in the form of disoproxil ester, which is deesterified to achieve a bioavailability of more than 20%."2.44[Tenofovir: pharmacology and interactions]. ( Azanza, JR; García Quetglas, E; Gómez-Giu, A; Sádaba, B, 2008)
"Acute renal failure is common in HIV-infected patients and is associated with acute infection and medication-related nephrotoxicity."2.44HIV-1 infection and the kidney: an evolving challenge in HIV medicine. ( de Silva, TI; Dockrell, DH; Griffin, MD; Post, FA, 2007)
" These data have now provided a clear and clinically relevant understanding of the individual profiles of drugs within the nucleoside analogue reverse transcriptase inhibitor , HIV protease inhibitor and non-nucleoside analogue reverse transcriptase inhibitor drug classes, and have provided a rational basis for assessing and monitoring these adverse effects in clinical practice."2.43Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. ( Mallal, S; Nolan, D; Reiss, P, 2005)
"Renal fibrosis is an inevitable outcome of various manifestations of progressive chronic kidney diseases (CKD)."1.72The gut microbe Bacteroides fragilis ameliorates renal fibrosis in mice. ( Alolga, RN; Bian, XY; Chen, C; Jiang, H; Li, J; Liu, HL; Liu, SJ; Liu, YF; Shan, JJ; Si, ZL; Tan, NH; Wang, H; Wu, WH; Zhang, ZH; Zhou, W, 2022)
"Renal interstitial fibrosis is characterized by the development of myofibroblasts, originating from resident renal and immigrating cells."1.62Endothelin receptors in renal interstitial cells do not contribute to the development of fibrosis during experimental kidney disease. ( Broeker, KAE; Fuchs, MAA; Neder, TH; Schrankl, J; Wagner, C, 2021)
"In individuals with a history of PRT on TDF, 96 weeks of TAF was not associated with recurrent PRT or adverse effects on renal tubular function, bone turnover, or BMD."1.62Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate. ( Barbini, B; Burling, K; Campbell, L; Cromarty, B; Hamzah, L; Johnson, M; Jones, R; Post, FA; Samarawickrama, A; Williams, D; Winston, A, 2021)
"Hyperuricemia is an independent risk factor for chronic kidney disease (CKD)."1.56Pharmacological inhibition of fatty acid-binding protein 4 alleviated kidney inflammation and fibrosis in hyperuricemic nephropathy. ( Feng, Y; Fu, P; Guo, F; Huang, R; Liao, D; Ma, L; Shi, M; Zeng, X, 2020)
"Renal fibrosis is an inevitable course of all kinds of progressive chronic kidney disease (CKD)."1.564-Octyl itaconate protects against renal fibrosis via inhibiting TGF-β/Smad pathway, autophagy and reducing generation of reactive oxygen species. ( He, J; Tan, N; Tian, F; Wang, Z; Zhang, Z, 2020)
" In this report, we use metabolomics and proteomics with HK-2 cells and animal models to dissect the molecular pathways underlying nephropathy caused by TFV and its more toxic analog, adefovir (ADV)."1.46Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity. ( Chen, J; Chen, L; Cheng, L; Chi, W; Deng, H; Huo, Y; Lan, Z; Liu, X; Siegenthaler, JA; Song, W; Sun, K; Xu, L; Zhao, X, 2017)
"Renal fibrosis is a common pathological feature of the progression of chronic kidney disease."1.46Valproic acid attenuates renal fibrosis through the induction of autophagy. ( Doi, S; Doi, T; Kawaoka, K; Masaki, T; Nakashima, A; Ueno, T; Yamada, K, 2017)
"Our results demonstrate that apigenin regulates OAT1, and can cause TDI or herb-drug interaction (HDI) when used in combination with acyclovir or adefovir."1.46Apigenin, a novel candidate involving herb-drug interaction (HDI), interacts with organic anion transporter 1 (OAT1). ( Cao, Y; Chen, J; Fu, W; Li, H; Pang, J; Wu, T; Zhou, P, 2017)
"The long-term use of nucleotide analogs increased the risk of nephrotoxicity in patients with CHB."1.42Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand. ( Kittitrakul, C; Leowattana, W; Nontprasert, A; Phumratanaprapin, W; Poovorawan, K; Sriboonvorakul, N; Tangkijvanich, P; Thu, AM; Wilairatana, P, 2015)
"Hepatitis B virus recurrence within 12 months was 4."1.42Adefovir- or Lamivudine-Induced Renal Tubular Dysfunction after Liver Transplantation. ( Choi, GH; Choi, JS; Joo, DJ; Ju, MK; Kim, MS; Kim, SI; Lee, J; Lee, JG; Lee, JJ; Song, SH, 2015)
" The granule form carries a risk of dosing errors and has a particularly strong, unpleasant taste."1.40Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys. ( , 2014)
"Hypertension was diagnosed in 19%, dyslipidemia in 27%, and diabetes mellitus in 3%."1.40High prevalence of signs of renal damage despite normal renal function in a cohort of HIV-infected patients: evaluation of associated factors. ( Aiestarán, A; Bonet, J; Bonjoch, A; Clotet, B; Echeverría, P; Juega, J; Negredo, E; Pérez, V; Pérez-Alvarez, N; Puig, J; Romero, R, 2014)
"Adenine treatment in rats has been proposed as an animal model of anemia of CKD with high hepcidin levels that mirrors the condition in human patients."1.39A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. ( Babitt, JL; Brown, DE; Cappellini, MD; Chen, S; Hong, CC; Lin, HY; Stepanek, A; Sun, CC; Theurl, I; Vaja, V; Weiss, G, 2013)
" Modification of the dosing interval or discontinuation of ADV was required in seven and three patients, respectively, and none of them showed a further decline in the eGFR."1.38Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. ( Cho, HC; Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2012)
"With lamivudine as initial treatment, 62% of patients developed drug resistance after 4 years."1.36Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. ( Chan, TM; Choy, BY; Tang, CS; Yap, DY; Yuen, MF; Yung, S, 2010)
"All three patients progressed to ESRD, within 1 month following renal biopsy in two and after 9 months in one."1.36Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure. ( Boelkins, M; Broviac, J; Cornell, LD; Fidler, ME; Milliner, DS; Nasr, SH; Sethi, S, 2010)
"It became evident that tenofovir DF (TDF) causes a modest and gradual decline in GFR, however, the impact of long-term use of TDF on tubular function has not been fully evaluated."1.35Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. ( Hanabusa, H; Kinai, E, 2009)
" We report 12-month changes in renal profiles among 19 such patients (6 patients with history of and 13 patients with current renal disease) in the HIV Outpatient Study (HOPS) who initiated TDF-containing highly active antiretroviral therapy (HAART) during 2001-2005 with TDF dosed mostly at 300 mg once daily."1.35Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study. ( Brooks, JT; Buchacz, K; Moorman, A; Wood, KC; Young, B, 2009)
"Secondary hyperparathyroidism is characterized by increased parathyroid hormone (PTH) mRNA stability that leads to increased PTH mRNA and serum PTH levels."1.35Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD. ( Ben-Dov, IZ; Naveh-Many, T; Nechama, M; Silver, J, 2009)
"The SCOLTA Project is a prospective, observational, multicenter study involving 25 infectious disease departments in Italy created to assess the incidence of severe adverse events in patients receiving new antiretroviral drugs."1.35Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. ( Bonfanti, P; Carradori, S; De Socio, GV; Grosso, C; Landonio, S; Madeddu, G; Marconi, P; Melzi, S; Miccolis, S; Mura, MS; Penco, G; Quirino, T; Ricci, E; Rosella, E, 2008)
"The EAP enrolled 10 343 patients; serious adverse events (SAEs) were reported in 631 (6%)."1.34The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. ( Bischofberger, N; Chen, SS; Clotet, B; Cooper, DA; Curtis, S; Gazzard, B; Katlama, C; Lange, J; Lazzarin, A; Montaner, JS; Nelson, MR; Rooney, JF; Schewe, K; Smith, S; Wyatt, C, 2007)
"Despite the recent publication of case reports describing various manifestations of tenofovir-related nephrotoxicity, data regarding the incidence of and risk factors for this adverse effect are currently lacking."1.33Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. ( Antoniou, T; Chirhin, S; Gough, K; Govan, V; Loutfy, M; Raboud, J; Rachlis, A; Yoong, D, 2005)
"Renal involvement in patients with systemic lupus erythematosus (SLE) varies from none to full-blown disease."1.31The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. ( Chung, JH; Kim, HL; Kim, S; Kim, YS; Lee, DS; Lee, JS; Lim, CS; Yang, SH, 2002)
"We present a case in which acute renal failure developed after therapy with tenofovir DF in a patient with HIV and stable chronic kidney disease."1.31Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. ( Coca, S; Perazella, MA, 2002)
"When adenine was intravenously administered, UN slightly increased at 1 h, but creatinine was unchanged."1.29Nephrotoxicity induced by adenine and its analogs: relationship between structure and renal injury. ( Kadota, E; Kawaki, H; Minami, T; Nabeshima, M; Nakagawa, H; Namikawa, K; Okazaki, Y, 1994)
"Gout is principally a disease of middle-aged men."1.26Uric acid crystal-induced nephropathy: evidence for a specific renal lesion in a gouty family. ( Cameron, JS; Dillon, MJ; Farebrother, DA; Pincott, JR; Simmons, HA; Warren, DJ, 1981)

Research

Studies (200)

TimeframeStudies, this research(%)All Research%
pre-19908 (4.00)18.7374
1990's8 (4.00)18.2507
2000's62 (31.00)29.6817
2010's101 (50.50)24.3611
2020's21 (10.50)2.80

Authors

AuthorsStudies
Campbell, L2
Barbini, B2
Burling, K2
Cromarty, B1
Hamzah, L4
Johnson, M3
Jones, R3
Samarawickrama, A1
Williams, D2
Winston, A1
Post, FA5
Khan, MA1
Nag, P1
Grivei, A1
Giuliani, KTK1
Wang, X1
Diwan, V1
Hoy, W1
Healy, H1
Gobe, G1
Kassianos, AJ1
Zhou, Y2
Wei, M2
Zhang, M1
Zhang, J2
Tang, F1
Wu, X2
Liu, Z1
Wang, W1
Li, X2
Tang, S1
Meng, D1
Xia, W1
Wang, H3
Wu, Y1
Zhou, X1
Du, P1
Wang, T1
Yang, M1
Yin, H1
Nakayama, T1
Azegami, T1
Hayashi, K1
Hishikawa, A1
Yoshimoto, N1
Nakamichi, R1
Sugita, E1
Itoh, H2
Li, A1
Ambruso, SL1
Oto, OA1
Barry, M1
Edelstein, CL1
Haritha, CV1
Lingaraju, MC1
Mathesh, K1
Jadhav, SE1
Shyamkumar, TS1
Aneesha, VA1
Parida, S1
Singh, TU1
Kumar, D1
Zhou, W1
Wu, WH1
Si, ZL1
Liu, HL1
Jiang, H1
Liu, YF1
Alolga, RN1
Chen, C1
Liu, SJ1
Bian, XY1
Shan, JJ1
Li, J1
Tan, NH1
Zhang, ZH1
Peng, X1
Qiao, B1
Peng, M1
Deng, N1
Yu, R1
Tan, Z1
Kim, J1
Ha, S1
Son, M1
Kim, D2
Kim, MJ1
Kim, B1
Chung, HY1
Chung, KW1
Calderón-Garcidueñas, AL1
Barradas-Dermitz, DM1
Nolasco-Hipolito, C1
López-Amador, N1
Ajibola, OO1
Carvajal-Zarrabal, O1
Bailey, AC1
Ibrahim, F1
Musso, CG1
Tian, F1
Wang, Z1
He, J1
Zhang, Z1
Tan, N1
Klinkhammer, BM1
Djudjaj, S1
Kunter, U1
Palsson, R1
Edvardsson, VO1
Wiech, T1
Thorsteinsdottir, M1
Hardarson, S1
Foresto-Neto, O1
Mulay, SR1
Moeller, MJ1
Jahnen-Dechent, W1
Floege, J1
Anders, HJ1
Boor, P1
Awad, AM1
Saleh, MA1
Abu-Elsaad, NM1
Ibrahim, TM1
Surial, B1
Béguelin, C1
Chave, JP1
Stöckle, M1
Boillat-Blanco, N1
Doco-Lecompte, T1
Bernasconi, E1
Fehr, J1
Günthard, HF1
Schmid, P1
Walti, LN1
Furrer, H2
Rauch, A1
Wandeler, G1
Shi, M1
Guo, F1
Liao, D1
Huang, R1
Feng, Y1
Zeng, X1
Ma, L1
Fu, P1
Mei, H1
Wu, N1
Huang, X1
Cui, Z1
Xu, J1
Yang, X2
Zeng, F1
Wang, K1
Jung, SW1
Kim, DJ1
Kim, YG1
Moon, JY1
Jeong, KH1
Lee, SH1
Neder, TH1
Schrankl, J1
Fuchs, MAA1
Broeker, KAE1
Wagner, C1
Zhao, X1
Sun, K1
Lan, Z1
Song, W1
Cheng, L1
Chi, W1
Chen, J2
Huo, Y1
Xu, L1
Liu, X1
Deng, H1
Siegenthaler, JA1
Chen, L1
Gallagher, A1
Quan, D1
Gracey, DM1
Novick, TK1
Choi, MJ1
Rosenberg, AZ1
McMahon, BA1
Fine, D1
Atta, MG2
Law, YXT1
Lee, LS1
Wu, T1
Li, H1
Cao, Y2
Fu, W1
Zhou, P1
Pang, J1
Chan, L1
Asriel, B1
Eaton, EF1
Wyatt, CM2
Rivera-Valdés, JJ1
García-Bañuelos, J1
Salazar-Montes, A1
García-Benavides, L1
Dominguez-Rosales, A1
Armendáriz-Borunda, J1
Sandoval-Rodríguez, A1
Negredo, E4
Clotet, B4
Min, IS1
Lee, CH1
Shin, IS1
Lee, NE1
Son, HS1
Kim, SB1
Seo, SY1
Kim, SH1
Kim, SW1
Lee, SO1
Lee, ST1
Kim, IH1
Fong, TL1
Lee, BT1
Tien, A1
Chang, M1
Lim, C1
Ahn, A1
Bae, HS1
Dos Santos, IF1
Sheriff, S1
Amlal, S1
Ahmed, RPH1
Thakar, CV1
Amlal, H1
Garigali, G1
Marra, G1
Rizzo, V1
de Liso, F1
Berrettini, A1
Daudon, M3
Fogazzi, GB1
Yang, Y1
Wang, P1
Ma, Y1
Ito, S2
Ohno, Y1
Tanaka, T1
Kobuchi, S1
Ayajiki, K1
Manabe, E1
Masuyama, T1
Jun-Ichi, S1
Tsujino, T1
Qian, YY1
Dai, ZJ1
Ruan, LY1
Pan, YJ1
Jin, J1
Shi, MT1
Zhu, YX1
Wu, CM1
Hartono, JL1
Aung, MO1
Dan, YY1
Gowans, M1
Lim, K1
Lee, YM1
Lee, GH1
Low, HC1
Tan, PS1
Thwin, MA1
Soon, C1
Chiu, LL1
Khoo, MJ1
Koay, E1
Lim, SG1
Nishijima, T2
Shimbo, T1
Komatsu, H2
Takano, M2
Tanuma, J1
Tsukada, K1
Teruya, K1
Gatanaga, H2
Kikuchi, Y1
Oka, S2
Tanaka, M1
Suzuki, F1
Seko, Y1
Hara, T1
Kawamura, Y1
Sezaki, H1
Hosaka, T1
Akuta, N1
Kobayashi, M2
Suzuki, Y1
Saitoh, S1
Arase, Y1
Ikeda, K1
Kumada, H1
Ichchou, L1
Rist, S1
Lespessailles, E1
Prié, D1
Benhamou, CL1
Woratanarat, K1
Kanjanabuch, T1
Suankratay, C1
Funk, EK1
Shaffer, A1
Shivakumar, B1
Sneller, M1
Polis, MA1
Masur, H1
Heytens, L1
Nelson, A1
Kwan, R1
Kottilil, S1
Kohli, A1
Han, Y1
Xie, J1
Cui, Q1
Zhang, L1
Li, Y3
Song, X1
Zhu, T1
Li, T1
Foisy, MM1
Hughes, C1
Hills-Nieminen, C1
Singh, AE1
Joffe, AM1
Pradat, P1
Le Pogam, MA1
Okon, JB1
Trolliet, P1
Miailhes, P1
Brochier, C1
Maynard, M1
Bailly, F1
Zoulim, F1
Cotte, L1
Pammi, M1
Arumainayagam, J1
Kumari, B1
Ahmed-Jushuf, I1
Carlin, EM1
Chandramani, S1
Riddell, L1
Ghanem, M1
Das, S1
Tanaka, H1
Arai, M1
Tomoda, Y1
Wada, T1
Yago, K1
Satoh, M1
Giacomet, V2
Cattaneo, D2
Viganò, A2
Nannini, P1
Manfredini, V1
Ramponi, G1
Clementi, E1
Zuccotti, GV2
Myer, L1
Kamkuemah, M1
Kaplan, R1
Bekker, LG1
van Griensven, J2
Phirum, L1
Thai, S1
Buyze, J1
Lynen, L2
Koenig, KF1
Kalbermatter, S1
Menter, T1
Graber, P1
Kiss, D1
Jabłonowska, E1
Wójcik, K1
Piekarska, A1
Ryom, L1
Mocroft, A1
Lundgren, JD1
Fung, J1
Seto, WK1
Lai, CL2
Yuen, MF2
Gervasoni, C1
Milazzo, L1
Pezzani, D1
Fucile, S1
Mwafongo, A1
Nkanaunena, K1
Zheng, Y1
Hogg, E1
Samaneka, W1
Mulenga, L1
Siika, A1
Currier, J1
Lockman, S1
Hughes, MD1
Hosseinipour, M1
Ezinga, M1
Wetzels, JF1
Bosch, ME1
van der Ven, AJ1
Burger, DM1
Jose, S1
Campbell, LJ2
Hill, T1
Fisher, M2
Leen, C1
Gilson, R1
Walsh, J1
Nelson, M1
Hay, P1
Chadwick, D1
Nitsch, D2
Sabin, CA1
Gupta, SK2
Anderson, AM1
Ebrahimi, R1
Fralich, T1
Graham, H1
Scharen-Guivel, V1
Flaherty, JF1
Fortin, C1
Kalayjian, RC1
Rachlis, A2
Milman, Z1
Axelrod, JH1
Heyman, SN1
Nachmansson, N1
Abramovitch, R1
Pujari, SN1
Smith, C1
Makane, A1
Youle, M1
Bele, V1
Joshi, K1
Dabhade, D1
Bhagani, S1
Zeng, Y1
Li, S1
Wu, J2
Chen, W1
Sun, H1
Peng, W1
Yu, X1
Jafari, A1
Khalili, H1
Dashti-Khavidaki, S1
Boettiger, DC1
Saphonn, V1
Lee, MP1
Phanuphak, P1
Pham, TT1
Heng Sim, BL1
Kumarasamy, N1
Van Nguyen, K1
Kantipong, P1
Kamarulzaman, A1
Chaiwarith, R1
Kiertiburanakul, S1
Law, MG1
Bonjoch, A2
Juega, J1
Puig, J2
Pérez-Alvarez, N2
Aiestarán, A1
Echeverría, P2
Pérez, V1
Romero, R1
Bonet, J1
Gorriz, JL1
Gutiérrez, F3
Trullàs, JC1
Arazo, P1
Arribas, JR1
Barril, G1
Cervero, M1
Cofán, F1
Domingo, P1
Estrada, V1
Fulladosa, X1
Galindo, MJ1
Gràcia, S1
Iribarren, JA1
Knobel, H1
López-Aldeguer, J1
Lozano, F1
Martínez-Castelao, A1
Martínez, E1
Mazuecos, MA1
Miralles, C1
Montañés, R1
Palacios, R1
Pérez-Elías, MJ1
Portilla, J1
Praga, M1
Quereda, C1
Rivero, A1
Santamaría, JM1
Sanz, J2
Miró, JM1
Maggi, P2
Montinaro, V2
Leone, A1
Fasano, M1
Volpe, A2
Bellacosa, C2
Grattagliano, V1
Coladonato, L1
Lapadula, G1
Santantonio, T1
Angarano, G2
Crean, D1
Bellwon, P1
Aschauer, L1
Limonciel, A1
Moenks, K1
Hewitt, P1
Schmidt, T1
Herrgen, K1
Dekant, W1
Lukas, A1
Bois, F1
Wilmes, A1
Jennings, P1
Leonard, MO1
Mandala, J1
Nanda, K1
Wang, M1
De Baetselier, I1
Deese, J1
Lombaard, J1
Owino, F1
Malahleha, M1
Manongi, R1
Taylor, D1
Van Damme, L1
Mitra, S1
Priscilla, R1
Rajeev, K1
Sauradeep, S1
Rajkumar, S1
Cherian, AO1
Shimizu, M1
Furusyo, N1
Ikezaki, H1
Ogawa, E1
Hayashi, T1
Ihara, T1
Harada, Y1
Toyoda, K1
Murata, M1
Hayashi, J1
Lee, JG1
Lee, J1
Lee, JJ1
Song, SH1
Ju, MK1
Choi, GH1
Kim, MS1
Choi, JS1
Kim, SI1
Joo, DJ1
Thu, AM1
Poovorawan, K1
Kittitrakul, C1
Nontprasert, A1
Sriboonvorakul, N1
Phumratanaprapin, W1
Tangkijvanich, P1
Leowattana, W1
Wilairatana, P1
Kamijo-Ikemori, A1
Sugaya, T1
Hibi, C1
Nakamura, T1
Murase, T1
Oikawa, T1
Hoshino, S1
Hisamichi, M1
Hirata, K1
Kimura, K1
Shibagaki, Y1
Kawaoka, K1
Doi, S1
Nakashima, A1
Yamada, K1
Ueno, T1
Doi, T1
Masaki, T1
Luo, Q1
Deng, Y1
Cheng, F1
Kang, J1
Zhong, S1
Zhang, D1
Zeng, W1
Hayashi, S1
Oe, Y1
Fushima, T1
Sato, E1
Sato, H1
Takahashi, N1
Libório, AB1
Andrade, L1
Pereira, LV1
Sanches, TR1
Shimizu, MH1
Seguro, AC1
Crane, HM1
Kestenbaum, B1
Harrington, RD1
Kitahata, MM1
Winston, J2
Deray, G3
Hawkins, T1
Szczech, L1
Wyatt, C2
Young, B2
Nechama, M1
Ben-Dov, IZ3
Silver, J2
Naveh-Many, T2
Azanza, JR1
García Quetglas, E1
Sádaba, B1
Gómez-Giu, A1
Pulido, F1
Fiorante, S1
Barril Cuadrado, G1
de Los Santos Gil, I1
Mallolas, J1
Terai, K1
Nara, H1
Takakura, K1
Mizukami, K1
Sanagi, M1
Fukushima, S1
Fujimori, A1
Okada, M1
Kinai, E1
Hanabusa, H1
Romero, E1
Hernández, JM1
Jarilla, F1
Woodward, CL1
Hall, AM3
Williams, IG1
Madge, S1
Copas, A1
Nair, D1
Edwards, SG1
Johnson, MA1
Connolly, JO2
Buchacz, K1
Moorman, A1
Wood, KC1
Brooks, JT1
Gallant, JE4
Moore, RD2
Rodriguez-Novoa, S4
Labarga, P4
Soriano, V4
Galitzer, H1
Nasr, SH1
Sethi, S1
Cornell, LD1
Milliner, DS1
Boelkins, M1
Broviac, J1
Fidler, ME1
Agarwala, R1
Mohan, S1
Herlitz, LC1
Cheng, JT1
Wever, K1
van Agtmael, MA1
Carr, A1
Flandre, P1
Oyama, Y1
Hashiguchi, T1
Taniguchi, N1
Tancharoen, S1
Uchimura, T1
Biswas, KK1
Kawahara, K1
Nitanda, T1
Umekita, Y1
Lotz, M1
Maruyama, I1
D'avolio, A1
Barreiro, P1
Albalate, M1
Vispo, E1
Solera, C1
Siccardi, M1
Bonora, S2
Di Perri, G2
Alvarez, E1
Crum-Cianflone, N1
Ganesan, A1
Teneza-Mora, N1
Riddle, M1
Medina, S1
Barahona, I1
Brodine, S1
Yap, DY1
Tang, CS1
Yung, S1
Choy, BY1
Chan, TM1
Shuvy, M1
Cooper, RD2
Wiebe, N1
Smith, N1
Keiser, P1
Naicker, S1
Tonelli, M2
Langer, S1
Kokozidou, M1
Heiss, C1
Kranz, J1
Kessler, T1
Paulus, N1
Krüger, T1
Jacobs, MJ1
Lente, C1
Koeppel, TA1
Soler-Palacín, P1
Melendo, S1
Noguera-Julian, A1
Fortuny, C1
Navarro, ML1
Mellado, MJ1
Garcia, L1
Uriona, S1
Martín-Nalda, A1
Figueras, C1
Hendry, BM1
Calza, L2
Trapani, F2
Tedeschi, S1
Piergentili, B1
Manfredi, R2
Colangeli, V2
Viale, P2
Gracey, D1
Post, J1
MacLeod, C1
McKenzie, P1
Harbord, N1
Yao, F1
Zhang, R1
Fu, R1
He, W1
Pushpakom, SP1
Liptrott, NJ1
Albalater, M1
Hopper-Borge, E1
Back, DJ1
Khoo, S1
Pirmohamed, M1
Owen, A1
Sopheak, T1
Koole, O1
Verpooten, GA1
Kim, YJ1
Cho, HC1
Sinn, DH1
Gwak, GY1
Choi, MS1
Koh, KC1
Paik, SW1
Yoo, BC1
Lee, JH1
Li, SW1
Hu, LJ1
Wu, QH1
Huang, P1
Cao, HY1
Vrouenraets, SM1
Wit, FW1
Fernandez Garcia, E1
Moyle, GJ1
Jackson, AG1
Allavena, C1
Raffi, F1
Jayaweera, DT1
Mauss, S2
Katlama, C2
Slama, L1
Hardy, WD1
Dejesus, E1
van Eeden, A1
Reiss, P2
Yoshino, M1
Yagura, H1
Kushida, H1
Yonemoto, H1
Bando, H1
Ogawa, Y1
Yajima, K1
Kasai, D1
Taniguchi, T1
Watanabe, D1
Nishida, Y2
Kuwahara, T1
Uehira, T1
Shirasaka, T1
Stöhr, W1
Reid, A1
Walker, AS1
Ssali, F1
Munderi, P1
Mambule, I1
Kityo, C1
Grosskurth, H1
Gilks, CF1
Gibb, DM1
Hakim, J1
Schleenvoigt, BT1
Stallmach, A1
Pletz, MW1
Pietanza, S1
Graziano, G1
Strippoli, GF1
Gupta, A1
Bugeja, A1
Kirpalani, D1
Plaisier, E1
Lescure, FX1
Ronco, P1
Pontrelli, G1
Cotugno, N1
Amodio, D1
Zangari, P1
Tchidjou, HK1
Baldassari, S1
Palma, P1
Bernardi, S1
Islam, FM1
Jansson, J1
Wilson, DP1
Gish, RG1
Clark, MD1
Kane, SD1
Shaw, RE1
Mangahas, MF1
Baqai, S1
Bollée, G1
Harambat, J1
Bensman, A1
Knebelmann, B1
Ceballos-Picot, I1
Rossotti, R1
Moioli, MC1
Chianura, L1
Errante, I1
Orcese, C1
Orso, M1
Schiantarelli, C1
Schlacht, I1
Travi, G1
Vigo, B1
Villa, MR1
Volonterio, A1
Puoti, M1
Estany, C1
Higasa, K1
Tsuchiya, K1
Hayashida, T1
Salvadori, C1
Magistrelli, E1
Di Bari, MA1
Borderi, M1
Laprise, C1
Baril, JG1
Dufresne, S1
Trottier, H1
Coffin, CS1
Fung, SK1
Ma, MM1
Sun, CC1
Vaja, V1
Chen, S1
Theurl, I1
Stepanek, A1
Brown, DE1
Cappellini, MD1
Weiss, G1
Hong, CC1
Lin, HY1
Babitt, JL1
Skowron, G1
Kuritzkes, DR1
Thompson, MA1
Squires, KE1
Goodwin, SD1
Dusak, BA1
Tolson, JM1
Stevens, M1
Yuen, GJ1
Rooney, JF2
Kim, HL1
Lee, DS1
Yang, SH1
Lim, CS1
Chung, JH1
Kim, S1
Lee, JS1
Kim, YS1
Coca, S1
Perazella, MA3
Antoniou, T2
Narita, I1
Goto, S1
Saito, N1
Song, J1
Omori, K1
Kondo, D1
Sakatsume, M1
Gejyo, F1
KINOSHITA, Y2
JAHRMAERKER, H1
Izzedine, H2
Isnard-Bagnis, C1
Hulot, JS2
Vittecoq, D2
Cheng, A2
Jais, CK1
Launay-Vacher, V2
Masiá, M2
Padilla, S2
Ramos, JM1
Pascual, J1
Saumoy, M1
Vidal, F1
Peraire, J1
Sauleda, S1
Vea, AM1
Viladés, C1
Ribera, E1
Richart, C1
Rifkin, BS1
Koguchi, T1
Koguchi, H1
Nakajima, H1
Takano, S1
Yamamoto, Y1
Innami, S1
Maekawa, A1
Tadokoro, T1
Berger, F1
Schmutz, G1
Staszewski, S1
Parish, MA1
Keruly, JC1
Nolan, D1
Mallal, S1
Raboud, J1
Chirhin, S1
Yoong, D1
Govan, V1
Gough, K1
Loutfy, M1
Jülg, BD1
Bogner, JR1
Crispin, A1
Goebel, FD1
Cánovas, V1
Orozco, C1
Hussain, S1
Khayat, A1
Tolaymat, A1
Rathore, MH1
Cirino, CM1
Kan, VL1
Shepp, DH1
Panda, A1
Yang, AM1
Li, YQ1
Li, HS1
Song, CS1
Ren, Y1
Yin, JX1
Madeddu, G2
Quirino, T2
Carradori, S2
Ricci, E2
Grosso, C2
Penco, G2
De Socio, G1
Rossella, E1
Palvarini, L1
Marconi, P2
Melzi, S2
Mura, MS2
Bonfanti, P2
Tan, J1
Lok, AS1
Sax, PE1
Klotman, PE1
Schiff, E1
Hadziyannis, S1
Neuhaus, P1
Terrault, N1
Colombo, M1
Tillmann, H1
Samuel, D1
Zeuzem, S1
Villeneuve, JP1
Arterburn, S1
Borroto-Esoda, K1
Brosgart, C1
Chuck, S1
Gitman, MD1
Hirschwerk, D1
Baskin, CH1
Singhal, PC1
Gérard, L1
Chazallon, C1
Taburet, AM1
Girard, PM1
Aboulker, JP1
Piketty, C1
Nelson, MR1
Montaner, JS1
Cooper, DA1
Gazzard, B1
Lazzarin, A1
Schewe, K1
Lange, J1
Curtis, S1
Chen, SS1
Smith, S1
Bischofberger, N1
De Socio, GV1
Rosella, E1
Miccolis, S1
Landonio, S1
Fux, CA1
Christen, A1
Zgraggen, S1
Mohaupt, MG1
Martelli, L1
Cafarelli, L1
Borgonovo, S1
Beretta, S1
Rombolà, G1
Mora, S1
Hou, P1
Chen, Y1
Ding, J1
Li, G1
Zhang, H1
de Silva, TI1
Griffin, MD1
Dockrell, DH1
Essig, M1
Duval, X1
Kaied, FA1
Iordache, L1
Gervais, A1
Longuet, P1
Blanchet, F1
Peytavin, G1
Leport, C1
Szczech, LA1
Goicoechea, M1
Liu, S1
Best, B1
Sun, S1
Jain, S1
Kemper, C1
Witt, M1
Diamond, C1
Haubrich, R1
Louie, S1
Hu, BC1
Chu, SL1
Wang, GL1
Gao, PJ1
Zhu, DL1
Wang, JG1
Fine, DM1
Lucas, GM1
He, LQ1
Bounous, G1
Sutherland, NG1
Mcardle, AH1
Gurd, FN1
Farebrother, DA1
Pincott, JR1
Simmons, HA1
Warren, DJ1
Dillon, MJ1
Cameron, JS1
Konishi, N1
Takeshita, K1
Yasui, H1
Minami, T1
Nakagawa, H1
Nabeshima, M1
Kadota, E1
Namikawa, K1
Kawaki, H1
Okazaki, Y1
Tsuda, H1
Matsumoto, K1
Iwase, T1
Baba, H1
Yokozawa, T2
Fujioka, K1
Oura, H2
Nonaka, G1
Nishioka, I1
Estepa-Maurice, L1
Hennequin, C1
Marfisi, C1
Bader, C1
Lacour, B1
Highleyman, L1
Gröbner, W1
Walter-Sack, I1
Story, DL1
Shrader, RE1
Theriault, LL1
Lumijarvi, DL1
Shenoy, TS1
Savaiano, DA1
Shaffer, RH1
Ho, CY1
Clifford, AJ1
Fujitsuka, N1
Delbarre, F1
Cartier, P1
Auscher, C1
de Géry, A1
Hamet, M1
Forbes, RM1

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Cohort Study to Assess the Safety and Efficacy of Replacing Tenofovir Disoproxil Fumarate by Tenofovir Alafenamide in HIV/HBV-coinfected Patients With Mild or Moderate Renal Dysfunction[NCT03115736]Phase 224 participants (Actual)Interventional2017-05-23Completed
"Analysis of Proximal Renal Tubular Function of Real World Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF"[NCT02957994]Phase 482 participants (Actual)Interventional2016-12-22Active, not recruiting
The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With Tenofovir Disoproxil Fumarate[NCT05313477]Phase 464 participants (Anticipated)Interventional2022-05-01Recruiting
Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients[NCT00872417]Phase 4750 participants (Anticipated)Interventional2009-03-31Not yet recruiting
Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide as Part of Salvage Antiretroviral Regimens in Patients With Uncontrolled Viremia and Drug-Resistant HIV Infection[NCT02556333]Phase 21 participants (Actual)Interventional2015-09-16Terminated
Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Effectiveness and Safety Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women[NCT00625404]Phase 32,120 participants (Actual)Interventional2009-05-31Completed
Severe Impairment of Solute-Free Water Clearance in Patients With HIV Infection[NCT01869010]30 participants (Actual)Observational2010-01-31Completed
Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir[NCT02588287]14 participants (Actual)Interventional2015-11-30Completed
Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.[NCT03126370]Phase 410 participants (Actual)Interventional2018-01-08Completed
Impact of Vitamin D Enteral Supplementation on Hepcidin Serum Levels and Transfusion Requirements in Surgical and Critically Ill Patients[NCT03001687]40 participants (Anticipated)Interventional2017-01-31Recruiting
Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients[NCT00551655]684 participants (Actual)Observational2007-05-31Completed
Safety and Efficacy of Tenofovir Alafenamide for Chronic Hepatitis B Patients With Decompensated Liver Disease[NCT04683341]Phase 4100 participants (Anticipated)Interventional2020-09-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

HIV RNA Change From Baseline to Day 10

An HIV RNA decline of >=0.5 log by day 10 will be considered to be an adequate virologic response, to proceed to the second phase of the study. (NCT02556333)
Timeframe: 10 days

Interventionlog HIV RNA copies/mL (Number)
TAF Treatment0.01

CD4+ T-cell Count

CD4+ T-cell Count at the Time of HIV Seroconversion through 16 weeks (NCT00625404)
Timeframe: Up to 16 weeks

Interventioncells/mL (Mean)
Truvada Arm579.3
Placebo Arm601.4

Confirmed Grade 2 or Higher Serum Creatinine Toxicity

Repeat specimens were collected to confirm chemistry toxicities. Grade 2 or higher serum creatinine toxicity was defined as ≥1.4 times the upper limit of normal (NCT00625404)
Timeframe: cumulative toxicity through 52 weeks of product use and 4 weeks post product

Interventionparticipants (Number)
Truvada Arm4
Placebo Arm2

Confirmed Grade 3 or Higher ALT Elevation

Grade 3 or higher ALT elevation was defined as ≥ 2.6 times the upper limit of normal (NCT00625404)
Timeframe: Through 52 weeks on product and 4 weeks post-product

Interventionparticipants (Number)
Truvada Arm6
Placebo Arm8

Confirmed Grade 3 or Higher AST Elevation

Grade 3 or higher AST elevation was defined as ≥ 2.6 times the upper limit of normal (NCT00625404)
Timeframe: Through 52 weeks on product and 4 weeks post-product

Interventionparticipants (Number)
Truvada Arm3
Placebo Arm1

Confirmed Grade 3 or Higher Reduction in Phosphorus

Repeat specimens were collected to confirm chemistry toxicities. Grade 3 phosphorus reduction was defined as ≤2.4mg/dL (NCT00625404)
Timeframe: Through 52 weeks on product and 4 weeks post-product

Interventionparticipants (Number)
Truvada Arm45
Placebo Arm40

Frequency of Adverse Events (AEs) During and Within 4 Weeks After Study Product Administration

The total number of adverse events in the placebo and Truvada arms during and within 4 weeks after study product administration. (NCT00625404)
Timeframe: 10-26 months per site

InterventionNumber of adverse events (Number)
Truvada Arm2257
Placebo Arm2384

FTC and/or Tenofovir Resistance

"Genotypic resistance to FTC and/or tenofovir at the time of HIV diagnosis and 4 weeks later. If resistance was present, testing was repeated at weeks 12, 24, 36 and 52 as necessary (resistance testing will stop if no resistance is detected).~participants were classified as having resistance if they had one or more visits in which resistance was detected, even if the resistance became undetectable over time." (NCT00625404)
Timeframe: up to 52 weeks

Interventionparticipants (Number)
Truvada Arm3
Placebo Arm1

HIV Infection

HIV Seroconversion, with time to infection refined based on PCR results obtained from stored specimens. (NCT00625404)
Timeframe: Cumulative HIV infection between enrollment and 52 weeks

Interventionparticipants (Number)
Truvada Arm33
Placebo Arm35

Participant Report of Change in Number of Sexual Partners

Difference in mean number of reported sexual partners between final study visit and enrollment visit (NCT00625404)
Timeframe: Up to 52 weeks

Interventionmean number of sexual partners (Mean)
Truvada Arm-0.14
Placebo Arm-0.13

Pill Counts and Participant Report of Adherence to Once-daily Pill Taking

Pill counts and participant report of adherence to once-daily pill taking reported as mean days study product could have been used according to pill counts (NCT00625404)
Timeframe: Up to 52 weeks

Interventionpercentage of days (Mean)
Truvada Arm87
Placebo Arm89

Plasma HIV RNA Level (HIV-1 Viral Load)

Viral load at the time of HIV detection, HIV conversion and through 16 weeks (NCT00625404)
Timeframe: up to 16 weeks

Interventionlog copies/mL (Log Mean)
Truvada Arm4.40
Placebo Arm4.37

Pregnancy Complications

Reported complications during pregnancy, including spontaneous abortion, vaginal or uterine bleeding, emergency c-section and other complications (NCT00625404)
Timeframe: up to 60 weeks

Interventionparticipants (Number)
Truvada Arm20
Placebo Arm10

Change From Week 12 Plasma Tenofovir Area Under the Plasma Concentration vs. Time Curve From Time 0 to 24 Hours (AUC0-24) at 24 and 28 Weeks

Compare plasma tenofovir AUC0-24 between TAF with boosted PI vs. TDF with boosted PI (Phase 2 vs. 1), and between TAF with boosted PI and LDV/SOF vs. TDF with boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 weeks and 28 weeks

Interventionng*h/mL (Geometric Mean)
TDF With a Boosted PI3466
TAF With a Boosted PI743
TAF With a Boosted PI and LDV/SOF868

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS)

Compare tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 and 28 weeks

Interventionfmol/2x7mm punches (Geometric Mean)
TDF With a Boosted PI36014
TAF With a Boosted PI6735
TAF With a Boosted PI and LDV/SOF6100

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs) at 24 and 28 Weeks

Compare tenofovir-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1). (NCT03126370)
Timeframe: 12 weeks, and 24 weeks and 28 weeks

Interventionfmol/10^6 cells (Geometric Mean)
TDF With a Boosted PI83.0
TAF With a Boosted PI926
TAF With a Boosted PI and LDV/SOF1129

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: eGFR

Change in estimated glomerular filtration rate (eGFR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

InterventionmL/min/1.73 m^2 (Geometric Mean)
TDF With a Boosted PI86.7
TAF With a Boosted PI91.0
TAF With a Boosted PI and LDV/SOF88.1

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: UPCR

Change in estimated glomerular filtration rate (eGFR) and renal biomarkers: Urine protein to creatinine ratio (UPCR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

Interventionmg/g (Geometric Mean)
TDF With a Boosted PI134
TAF With a Boosted PI118
TAF With a Boosted PI and LDV/SOF97.3

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: B2M/Cr Ratio, and RBP/Cr Ratio

Change in renal biomarkers: urinary beta-2 microglobulin (B2M)/creatinine (Cr) ratio, and urinary retinol binding protein (RBP)/Cr ratio (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

,,
Interventionug/g (Geometric Mean)
β2M:Cr ratioRBP:Cr ratio
TAF With a Boosted PI224242
TAF With a Boosted PI and LDV/SOF178146
TDF With a Boosted PI419436

Reviews

26 reviews available for adenine and Kidney Diseases

ArticleYear
Functional and histological effects of Anthurium schlechtendalii Kunth extracts on adenine-induced kidney damage of adult Wistar rats.
    Toxicon : official journal of the International Society on Toxinology, 2023, Volume: 233

    Topics: Adenine; Adult; Animals; Araceae; Humans; Inflammation; Kidney; Kidney Diseases; Plant Extracts; Rat

2023
Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.
    Current opinion in nephrology and hypertension, 2018, Volume: 27, Issue:2

    Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Drug Interactions; Glomerular Filtration Rate; Hep

2018
Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons.
    Current opinion in HIV and AIDS, 2014, Volume: 9, Issue:1

    Topics: Adenine; Anti-Retroviral Agents; HIV Infections; Humans; Immunosuppression Therapy; Kidney Diseases;

2014
Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:3

    Topics: Acidosis, Lactic; Adenine; Administration, Oral; Antiviral Agents; Arabinofuranosyluracil; Dose-Resp

2014
Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.
    European journal of clinical pharmacology, 2014, Volume: 70, Issue:9

    Topics: Adenine; Animals; Anti-HIV Agents; HIV Infections; Humans; Incidence; Kidney Diseases; Organophospho

2014
Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis.
    Medicine, 2016, Volume: 95, Issue:50

    Topics: Adenine; Creatinine; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney; Kidney Diseas

2016
Kidney disease in patients with HIV infection and AIDS.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Dec-01, Volume: 47, Issue:11

    Topics: Adenine; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Risk Factors; Tenofovir

2008
[Tenofovir: pharmacology and interactions].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 8

    Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Biological Availability; Biotransformation; Child

2008
[Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 8

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cohort St

2008
[Management of renal toxicity in HIV-positive patients. What to measure, how to measure it and how frequently].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 8

    Topics: Adenine; Algorithms; Anti-HIV Agents; beta 2-Microglobulin; Clinical Trials as Topic; Cohort Studies

2008
Pharmacogenetics of tenofovir treatment.
    Pharmacogenomics, 2009, Volume: 10, Issue:10

    Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; HIV Infections; HIV-1; Humans; Kidney Diseases; Ki

2009
Renal toxicity associated with tenofovir use.
    Expert opinion on drug safety, 2010, Volume: 9, Issue:4

    Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Hu

2010
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Sep-01, Volume: 51, Issue:5

    Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Tenofovir

2010
Renal disease associated with antiretroviral therapy in the treatment of HIV.
    Nephron. Clinical practice, 2011, Volume: 118, Issue:3

    Topics: Adenine; Anti-Retroviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Indinavir; Kidney Disea

2011
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2011, Volume: 57, Issue:5

    Topics: Adenine; Animals; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Disea

2011
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2011, Volume: 57, Issue:5

    Topics: Adenine; Animals; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Disea

2011
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2011, Volume: 57, Issue:5

    Topics: Adenine; Animals; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Disea

2011
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2011, Volume: 57, Issue:5

    Topics: Adenine; Animals; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Disea

2011
Novel nephrotoxins.
    Advances in chronic kidney disease, 2011, Volume: 18, Issue:3

    Topics: Adenine; Alcohols; Angiogenesis Inhibitors; Anticonvulsants; Antipsychotic Agents; Dasatinib; Diphos

2011
[Kidney and HIV infection].
    Presse medicale (Paris, France : 1983), 2012, Volume: 41, Issue:3 Pt 1

    Topics: Adenine; AIDS-Associated Nephropathy; Anti-HIV Agents; Biopsy; Black People; ErbB Receptors; Female;

2012
Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis.
    BMC public health, 2012, Mar-23, Volume: 12

    Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Chronic

2012
Adenine phosphoribosyltransferase deficiency.
    Clinical journal of the American Society of Nephrology : CJASN, 2012, Volume: 7, Issue:9

    Topics: Adenine; Adenine Phosphoribosyltransferase; Allopurinol; Animals; Biomarkers; Disease Progression; E

2012
Update on tenofovir toxicity in the kidney.
    Pediatric nephrology (Berlin, Germany), 2013, Volume: 28, Issue:7

    Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Hepatitis B; HIV Infections; Humans; Kidney; Ki

2013
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardi

2005
[Renal toxicity in HIV-infected patients receiving HAART including tenofovir].
    Le infezioni in medicina, 2006, Volume: 14, Issue:3

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; HIV Infections;

2006
Renal safety of tenofovir disoproxil fumarate.
    The AIDS reader, 2007, Volume: 17, Issue:2

    Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; HIV Infections; Humans; Kidney; Kidney Diseases;

2007
HIV-1 infection and the kidney: an evolving challenge in HIV medicine.
    Mayo Clinic proceedings, 2007, Volume: 82, Issue:9

    Topics: Acute Disease; Acute Kidney Injury; Adenine; AIDS-Associated Nephropathy; Angiotensin-Converting Enz

2007
Kidney biopsy in HIV: beyond HIV-associated nephropathy.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 51, Issue:3

    Topics: Acute Disease; Adenine; AIDS-Associated Nephropathy; Anti-HIV Agents; Antiretroviral Therapy, Highly

2008
[A case of adenine phosphoribosyltransferase (APRT) deficiency discovered by urine examination].
    Nihon Jinzo Gakkai shi, 1994, Volume: 36, Issue:10

    Topics: Adenine; Adenine Phosphoribosyltransferase; Adult; Allopurinol; Crystallization; Homozygote; Humans;

1994

Trials

14 trials available for adenine and Kidney Diseases

ArticleYear
Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
    HIV medicine, 2020, Volume: 21, Issue:3

    Topics: Adenine; Alanine; Creatinine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine

2020
Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.
    BMC infectious diseases, 2013, Jul-01, Volume: 13

    Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Female; Glomerular Filtration Rate; HIV Infections; Hum

2013
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.
    AIDS (London, England), 2014, May-15, Volume: 28, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Creatinine; Deoxycytidine; Drug Therapy, Combination; Emtricitabin

2014
Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
    BMC pharmacology & toxicology, 2014, Dec-24, Volume: 15

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Blac

2014
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
    HIV medicine, 2011, Volume: 12, Issue:10

    Topics: Adenine; Adult; Atazanavir Sulfate; Deoxycytidine; Drug Administration Schedule; Dyslipidemias; Emtr

2011
Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
    Antiviral therapy, 2011, Volume: 16, Issue:7

    Topics: Adenine; Adult; Africa; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Creatinine; Did

2011
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
    The Journal of infectious diseases, 2002, Oct-01, Volume: 186, Issue:7

    Topics: Adenine; Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy

2002
Renal safety of tenofovir in HIV treatment-experienced patients.
    AIDS (London, England), 2004, Apr-30, Volume: 18, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; Humans; Kidney Disease

2004
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2005, Volume: 20, Issue:4

    Topics: Adenine; Adult; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Male; O

2005
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Apr-15, Volume: 40, Issue:8

    Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Creatinine; Female; HIV Infec

2005
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2007, Volume: 13, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2007
Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
    Antiviral therapy, 2007, Volume: 12, Issue:1

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cre

2007
Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study.
    Clinical drug investigation, 2007, Volume: 27, Issue:8

    Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Child, Preschool; Female; Glomerular Filtration Rate; H

2007
Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
    The Journal of infectious diseases, 2008, Jan-01, Volume: 197, Issue:1

    Topics: Adenine; Adult; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV P

2008

Other Studies

160 other studies available for adenine and Kidney Diseases

ArticleYear
Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.
    Journal of acquired immune deficiency syndromes (1999), 2021, 10-01, Volume: 88, Issue:2

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Creatinine; Cystatin C; Female; HIV Infections; Humans; Ki

2021
Adenine overload induces ferroptosis in human primary proximal tubular epithelial cells.
    Cell death & disease, 2022, 02-02, Volume: 13, Issue:2

    Topics: Adenine; Aldehydes; Animals; Epithelial Cells; Ferroptosis; Flavanones; Humans; Iron; Kidney Disease

2022
Adefovir accumulation in the renal interstitium triggers mast cell degranulation and promotes renal interstitial fibrosis.
    Toxicology letters, 2022, Apr-15, Volume: 359

    Topics: Adenine; Animals; Cell Degranulation; Disease Models, Animal; Fibrosis; Humans; Kidney Diseases; Kid

2022
Capsaicin ameliorates renal fibrosis by inhibiting TGF-β1-Smad2/3 signaling.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2022, Volume: 100

    Topics: Adenine; Animals; Cadherins; Capsaicin; Disease Models, Animal; Fibrosis; Kidney; Kidney Diseases; M

2022
Mucin-fused myeloid-derived growth factor (MYDGF164) exhibits a prolonged serum half-life and alleviates fibrosis in chronic kidney disease.
    British journal of pharmacology, 2022, Volume: 179, Issue:16

    Topics: Adenine; Animals; Disease Models, Animal; Fibrosis; Half-Life; Humans; Intercellular Signaling Pepti

2022
Vaccination against connective tissue growth factor attenuates the development of renal fibrosis.
    Scientific reports, 2022, 06-29, Volume: 12, Issue:1

    Topics: Adenine; Animals; Connective Tissue Growth Factor; Fibrosis; Kidney; Kidney Diseases; Mice; Renal In

2022
A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib.
    BMC nephrology, 2022, 07-23, Volume: 23, Issue:1

    Topics: Adenine; Aged, 80 and over; Endothelial Cells; ErbB Receptors; Glomerulonephritis, Membranoprolifera

2022
PRE-084 ameliorates adenine-induced renal fibrosis in rats.
    Tissue & cell, 2022, Volume: 79

    Topics: Adenine; Animals; Creatinine; Fibrosis; Keratins; Kidney Diseases; Matrix Metalloproteinase 2; Morph

2022
The gut microbe Bacteroides fragilis ameliorates renal fibrosis in mice.
    Nature communications, 2022, 10-14, Volume: 13, Issue:1

    Topics: Adenine; Animals; Bacteroides fragilis; Biological Products; Disease Models, Animal; Fibrosis; Gastr

2022
Gut-Kidney Impairment Process of Adenine Combined with
    Cells, 2022, 10-17, Volume: 11, Issue:20

    Topics: Acetic Acid; Adenine; Animals; Bacteroides; Colitis; Creatinine; Diarrhea; Disease Models, Animal; F

2022
TLR7 activation by miR-21 promotes renal fibrosis by activating the pro-inflammatory signaling pathway in tubule epithelial cells.
    Cell communication and signaling : CCS, 2023, 08-18, Volume: 21, Issue:1

    Topics: Adenine; Animals; Epithelial Cells; Fibrosis; Inflammation; Kidney Diseases; Mice; MicroRNAs; NF-kap

2023
4-Octyl itaconate protects against renal fibrosis via inhibiting TGF-β/Smad pathway, autophagy and reducing generation of reactive oxygen species.
    European journal of pharmacology, 2020, Apr-15, Volume: 873

    Topics: Adenine; Animals; Antioxidants; Autophagy; Fibrosis; Humans; Kidney Diseases; Male; Protective Agent

2020
Cellular and Molecular Mechanisms of Kidney Injury in 2,8-Dihydroxyadenine Nephropathy.
    Journal of the American Society of Nephrology : JASN, 2020, Volume: 31, Issue:4

    Topics: Adenine; Adenine Phosphoribosyltransferase; Adult; Animals; Cohort Studies; Diet; Disease Models, An

2020
Erlotinib can halt adenine induced nephrotoxicity in mice through modulating ERK1/2, STAT3, p53 and apoptotic pathways.
    Scientific reports, 2020, 07-13, Volume: 10, Issue:1

    Topics: Adenine; Animals; Disease Models, Animal; Fibrosis; Humans; Kidney; Kidney Diseases; MAP Kinase Sign

2020
Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
    Journal of acquired immune deficiency syndromes (1999), 2020, 10-01, Volume: 85, Issue:2

    Topics: Adenine; Aged; Alanine; Anti-HIV Agents; Female; Glomerular Filtration Rate; Hepatitis B; Hepatitis

2020
Pharmacological inhibition of fatty acid-binding protein 4 alleviated kidney inflammation and fibrosis in hyperuricemic nephropathy.
    European journal of pharmacology, 2020, Nov-15, Volume: 887

    Topics: Adenine; Animals; Biphenyl Compounds; Cytokines; Fatty Acid-Binding Proteins; Fibrosis; Hepatitis A

2020
Possible mechanisms by which silkworm faeces extract ameliorates adenine-induced renal anaemia in rats.
    Journal of ethnopharmacology, 2021, Feb-10, Volume: 266

    Topics: Adenine; Anemia; Animals; Bombyx; Disease Models, Animal; Erythropoietin; Feces; Hepcidins; Humans;

2021
Renal Aging Resembles a Continuum Between Normal and Diseased Kidneys That Potentiates Inflammatory Response to Injury.
    The journals of gerontology. Series A, Biological sciences and medical sciences, 2021, 02-25, Volume: 76, Issue:3

    Topics: Adenine; Aging; Animals; Cytokines; Disease Models, Animal; Inflammation; Kidney Diseases; Male; Mic

2021
Endothelin receptors in renal interstitial cells do not contribute to the development of fibrosis during experimental kidney disease.
    Pflugers Archiv : European journal of physiology, 2021, Volume: 473, Issue:10

    Topics: Adenine; Animals; Fibrosis; Gene Deletion; Gene Expression Regulation; Kidney; Kidney Diseases; Mice

2021
Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity.
    Scientific reports, 2017, 04-11, Volume: 7

    Topics: Adenine; Animals; Anti-HIV Agents; Cell Line; Cell Proliferation; Cell Survival; Glucose; Glycolysis

2017
Improvement in renal function and resolution of proteinuria in an HIV-infected patient switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Internal medicine journal, 2017, Volume: 47, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Drug Substitution; Female; HIV Infections; Humans; Kidney Diseas

2017
Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report.
    Medicine, 2017, Volume: 96, Issue:36

    Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Mitoc

2017
Sudden Flank Pain in a Patient Receiving Ibrutinib for Mantle Cell Lymphoma.
    JAMA oncology, 2018, Jan-01, Volume: 4, Issue:1

    Topics: Acute Disease; Adenine; Female; Flank Pain; Hematoma; Humans; Kidney Diseases; Lymphoma, Mantle-Cell

2018
Apigenin, a novel candidate involving herb-drug interaction (HDI), interacts with organic anion transporter 1 (OAT1).
    Pharmacological reports : PR, 2017, Volume: 69, Issue:6

    Topics: Acyclovir; Adenine; Animals; Antiviral Agents; Apigenin; Cell Survival; Chromatography, High Pressur

2017
Human adipose derived stem cells regress fibrosis in a chronic renal fibrotic model induced by adenine.
    PloS one, 2017, Volume: 12, Issue:12

    Topics: Adenine; Adipose Tissue; Animals; Cells, Cultured; Fibrosis; Gene Expression Profiling; Humans; Kidn

2017
Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
    Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:8

    Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance,

2018
Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate.
    Gut and liver, 2019, 01-15, Volume: 13, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Female; Glomerular Filtration Rate;

2019
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:5

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal

2019
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:5

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal

2019
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:5

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal

2019
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:5

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal

2019
Adenine acts in the kidney as a signaling factor and causes salt- and water-losing nephropathy: early mechanism of adenine-induced renal injury.
    American journal of physiology. Renal physiology, 2019, 04-01, Volume: 316, Issue:4

    Topics: Adenine; Animals; Aquaporin 2; Arginine Vasopressin; Cyclic AMP; Diet; Dose-Response Relationship, D

2019
A virtuous diagnostic and therapeutic roadmap triggered by a motivated and skilful urinary sediment examination.
    Clinica chimica acta; international journal of clinical chemistry, 2019, Volume: 492

    Topics: Adenine; Humans; Kidney Diseases; Urinalysis; Urologic Diseases

2019
Adefovir accumulation and nephrotoxicity in renal interstitium: Role of organic anion transporters of kidney.
    Life sciences, 2019, May-01, Volume: 224

    Topics: Adenine; Animals; Antiviral Agents; Kidney Diseases; Kidney Tubules; Organic Anion Transporters; Org

2019
Neutrophil/lymphocyte ratio elevation in renal dysfunction is caused by distortion of leukocyte hematopoiesis in bone marrow.
    Renal failure, 2019, Volume: 41, Issue:1

    Topics: Adenine; Aged; Aged, 80 and over; Animals; Biomarkers; Bone Marrow; Carbon; Cardiovascular Diseases;

2019
Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible?
    Drug design, development and therapy, 2019, Volume: 13

    Topics: Adenine; Aged; Dose-Response Relationship, Drug; Fanconi Syndrome; Female; Hepatitis B, Chronic; Hum

2019
Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; Asian People; Creatinine; Dose-Response Relationship, Drug; Female

2013
Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2013, Volume: 19, Issue:5

    Topics: Adenine; Adult; Alpha-Globulins; Anti-Retroviral Agents; beta 2-Microglobulin; Biomarkers; Chi-Squar

2013
Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.
    Journal of gastroenterology, 2014, Volume: 49, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; Creatinine; Drug Therapy, Combination; Female; Glomerular Fi

2014
Reversible increase in FGF23 in a hypophosphatemic renal and bone disease linked to antiviral therapy by adefovir.
    Joint bone spine, 2013, Volume: 80, Issue:6

    Topics: Adenine; Aged; Antiviral Agents; Bone Diseases; Female; Fibroblast Growth Factor-23; Fibroblast Grow

2013
Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: a prospective controlled study.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2013, Volume: 96, Issue:4

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Huma

2013
Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:9

    Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Com

2013
Tenofovir-related nephrotoxicity: an ongoing clinical challenge.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, Aug-01, Volume: 70, Issue:15

    Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organo

2013
Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis B, Chro

2013
Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
    International journal of clinical practice, 2013, Volume: 67, Issue:9

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cardiovascular Diseases; CD4 Lymphocyte Count; Cycl

2013
Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2013, Volume: 16, Issue:3

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Combinations;

2013
Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes.
    The Pediatric infectious disease journal, 2013, Volume: 32, Issue:10

    Topics: Adenine; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Kidney Diseases; Kidney Tubules; Ma

2013
Low prevalence of renal dysfunction in HIV-infected pregnant women: implications for guidelines for the prevention of mother-to-child transmission of HIV.
    Tropical medicine & international health : TM & IH, 2013, Volume: 18, Issue:11

    Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; Contraindications; Creatinine; F

2013
A clinical prediction score for targeted creatinine testing before initiating tenofovir-based antiretroviral treatment in Cambodia.
    Journal of acquired immune deficiency syndromes (1999), 2014, Apr-01, Volume: 65, Issue:4

    Topics: Adenine; Adult; Anti-HIV Agents; Cambodia; Clinical Medicine; Creatinine; Cross-Sectional Studies; D

2014
Recurrent bone fractures due to tenofovir-induced renal phosphate wasting.
    Scandinavian journal of infectious diseases, 2014, Volume: 46, Issue:3

    Topics: Adenine; Adult; Anti-HIV Agents; Fractures, Stress; HIV Infections; Humans; Kidney Diseases; Male; O

2014
Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.
    AIDS research and human retroviruses, 2014, Volume: 30, Issue:4

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Fat

2014
Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patients.
    AIDS (London, England), 2014, Jan-14, Volume: 28, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Kidney Diseases; Male; Oligop

2014
Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration.
    Antiviral therapy, 2014, Volume: 19, Issue:8

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Comorbidity; Cross-Sectional

2014
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.
    The Journal of infectious diseases, 2014, Aug-01, Volume: 210, Issue:3

    Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Female; Glomerular Fi

2014
Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Creatinine; Fanconi Syndrome; Female; Glomeru

2014
Assessment with unenhanced MRI techniques of renal morphology and hemodynamic changes during acute kidney injury and chronic kidney disease in mice.
    American journal of nephrology, 2014, Volume: 39, Issue:3

    Topics: Acute Kidney Injury; Adenine; Animals; Contrast Media; Hemodynamics; Kidney; Kidney Diseases; Magnet

2014
Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom.
    BMC infectious diseases, 2014, Mar-29, Volume: 14

    Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; India; Kidney Disea

2014
Autophagy inhibitors promoted aristolochic acid I induced renal tubular epithelial cell apoptosis via mitochondrial pathway but alleviated nonapoptotic cell death in mouse acute aritolochic acid nephropathy model.
    Apoptosis : an international journal on programmed cell death, 2014, Volume: 19, Issue:8

    Topics: Adenine; Animals; Apoptosis; Aristolochia; Aristolochic Acids; Autophagy; Chloroquine; Drugs, Chines

2014
Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys.
    Prescrire international, 2014, Volume: 23, Issue:149

    Topics: Adenine; Anti-HIV Agents; Bone Diseases; Child; Dose-Response Relationship, Drug; HIV Infections; Hu

2014
A clinical prediction tool for targeted pre-antiretroviral therapy creatinine testing applied to the TREAT Asia HIV observational database cohort.
    Journal of acquired immune deficiency syndromes (1999), 2014, Dec-01, Volume: 67, Issue:4

    Topics: Adenine; Anti-HIV Agents; Clinical Medicine; Creatinine; Decision Support Techniques; Female; HIV In

2014
High prevalence of signs of renal damage despite normal renal function in a cohort of HIV-infected patients: evaluation of associated factors.
    AIDS patient care and STDs, 2014, Volume: 28, Issue:10

    Topics: Adenine; Adult; Age Factors; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; D

2014
[Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients].
    Enfermedades infecciosas y microbiologia clinica, 2014, Volume: 32, Issue:9

    Topics: Adenine; Algorithms; Anti-HIV Agents; Biopsy; Cardiovascular Diseases; Disease Management; Evidence-

2014
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; Bone Diseases; Drug-Related Side Effects and Adverse Reactio

2015
Development of an in vitro renal epithelial disease state model for xenobiotic toxicity testing.
    Toxicology in vitro : an international journal published in association with BIBRA, 2015, Dec-25, Volume: 30, Issue:1 Pt A

    Topics: Adenine; Cell Line; Epithelium; Gene Expression Regulation; Humans; Hypoxia; Kidney Diseases; Kidney

2015
Renal tubular dysfunction associated with tenofovir therapy.
    The Journal of the Association of Physicians of India, 2014, Volume: 62, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Developing Countries; Diagnosis, Differential; Female;

2014
Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B.
    World journal of gastroenterology, 2015, Feb-21, Volume: 21, Issue:7

    Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Chi-Square Distribution; Fem

2015
Adefovir- or Lamivudine-Induced Renal Tubular Dysfunction after Liver Transplantation.
    Medicine, 2015, Volume: 94, Issue:38

    Topics: Adenine; Female; Hepatitis B; Humans; Incidence; Kidney Diseases; Lamivudine; Liver Transplantation;

2015
Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand.
    BMC pharmacology & toxicology, 2015, Dec-14, Volume: 16

    Topics: Adenine; Adult; Antiviral Agents; Creatinine; Female; Follow-Up Studies; Guanine; Hepatitis B, Chron

2015
Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury.
    American journal of physiology. Renal physiology, 2016, 06-01, Volume: 310, Issue:11

    Topics: Adenine; Animals; Biomarkers; Fatty Acid-Binding Proteins; Febuxostat; Kidney; Kidney Diseases; Male

2016
Valproic acid attenuates renal fibrosis through the induction of autophagy.
    Clinical and experimental nephrology, 2017, Volume: 21, Issue:5

    Topics: Actins; Adenine; Animals; Autophagy; Cell Line; Collagen Type I; Cytoprotection; Disease Models, Ani

2017
Protease-activated receptor 2 exacerbates adenine-induced renal tubulointerstitial injury in mice.
    Biochemical and biophysical research communications, 2017, 01-29, Volume: 483, Issue:1

    Topics: Adenine; Animals; Enzyme-Linked Immunosorbent Assay; Factor V; Factor Xa; Fibrin; Fibrosis; Gene Exp

2017
Rosiglitazone reverses tenofovir-induced nephrotoxicity.
    Kidney international, 2008, Volume: 74, Issue:7

    Topics: Adenine; Animals; Drug-Related Side Effects and Adverse Reactions; Glomerular Filtration Rate; Hypog

2008
Tenofovir-associated decline in renal function.
    The Journal of infectious diseases, 2008, Sep-15, Volume: 198, Issue:6

    Topics: Adenine; Adult; Anti-HIV Agents; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease In

2008
Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD.
    American journal of physiology. Renal physiology, 2009, Volume: 296, Issue:4

    Topics: 3' Untranslated Regions; Adenine; Aniline Compounds; Animals; Calcium; Chronic Disease; Disease Mode

2009
[Conclusions. Tenofovir].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 8

    Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; HIV Reverse Transcriptase; Hu

2008
Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels.
    British journal of pharmacology, 2009, Volume: 156, Issue:8

    Topics: Adenine; Animals; Aortic Diseases; Biomarkers; Blood Urea Nitrogen; Calcinosis; Calcium; Calcium Car

2009
Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:4

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Drug Therapy, Combination; Glomerular Filtration Rate; HIV In

2009
[Renal tuberculosis and human immunodeficiency virus infection].
    Enfermedades infecciosas y microbiologia clinica, 2009, Volume: 27, Issue:6

    Topics: Acute Kidney Injury; Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral

2009
Tenofovir-associated renal and bone toxicity.
    HIV medicine, 2009, Volume: 10, Issue:8

    Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Fanconi Syndrome; Female; Glycosuria; HIV Infections; H

2009
Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
    AIDS patient care and STDs, 2009, Volume: 23, Issue:8

    Topics: Adenine; Adult; Aged; Ambulatory Care Facilities; Anti-HIV Agents; Antiretroviral Therapy, Highly Ac

2009
HIV therapy may be given safely in resource-limited settings without routine laboratory monitoring.
    AIDS patient care and STDs, 2009, Volume: 23, Issue:8

    Topics: Adenine; Anti-HIV Agents; Diagnostic Tests, Routine; Glomerular Filtration Rate; Health Resources; H

2009
Renal function with use of a tenofovir-containing initial antiretroviral regimen.
    AIDS (London, England), 2009, Sep-24, Volume: 23, Issue:15

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtratio

2009
Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease.
    Kidney international, 2010, Volume: 77, Issue:3

    Topics: Adenine; Animals; Chronic Disease; Down-Regulation; Fibroblast Growth Factor-23; Fibroblast Growth F

2010
Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:6

    Topics: Adenine; Adenine Phosphoribosyltransferase; Adult; Allopurinol; Crystallization; Diagnosis, Differen

2010
The case: 41-year-old HIV patient with proteinuria and progressive renal dysfunction. Tenofovir toxicity.
    Kidney international, 2010, Volume: 77, Issue:5

    Topics: Adenine; Adult; Anti-HIV Agents; Biopsy; Disease Progression; Humans; Kidney; Kidney Diseases; Kidne

2010
Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 55, Issue:1

    Topics: Adenine; Anti-HIV Agents; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Kidney Disease

2010
Tenofovir and changes in renal function.
    AIDS (London, England), 2010, Feb-20, Volume: 24, Issue:4

    Topics: Adenine; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Re

2010
High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy.
    Laboratory investigation; a journal of technical methods and pathology, 2010, Volume: 90, Issue:6

    Topics: Adenine; Animals; Blood Urea Nitrogen; Chemokine CCL2; Creatinine; Epithelial Cells; Granuloma; HMGB

2010
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.
    AIDS (London, England), 2010, Apr-24, Volume: 24, Issue:7

    Topics: Adenine; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Organophosp

2010
Prevalence and factors associated with renal dysfunction among HIV-infected patients.
    AIDS patient care and STDs, 2010, Volume: 24, Issue:6

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Fem

2010
Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.
    Transplantation, 2010, Aug-15, Volume: 90, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Female; Guanine; H

2010
Acquired DHA nephropathy in rats.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:10

    Topics: Adenine; Animals; Crystallization; Kidney Diseases; Rats

2010
Chronic kidney disease aggravates arteriovenous fistula damage in rats.
    Kidney international, 2010, Volume: 78, Issue:12

    Topics: Adenine; Animals; Arteriovenous Shunt, Surgical; Blood Pressure; Calcinosis; Chronic Disease; Constr

2010
Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens.
    AIDS (London, England), 2011, Jan-14, Volume: 25, Issue:2

    Topics: Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Child; Female; HIV Infections; Humans; K

2011
Is tenofovir-related renal toxicity incompletely reversible?
    Journal of acquired immune deficiency syndromes (1999), 2011, Mar-01, Volume: 56, Issue:3

    Topics: Adenine; Adult; Anti-HIV Agents; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases

2011
Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.
    Scandinavian journal of infectious diseases, 2011, Volume: 43, Issue:8

    Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections;

2011
Improvement in chronic renal impairment following the discontinuation of tenofovir in two HIV-infected patients.
    Nephrology (Carlton, Vic.), 2011, Volume: 16, Issue:4

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Biopsy; Chronic Disease

2011
[Preventive and therapeutic effects of quercetin on hyperuricemia and renal injury in rats].
    Wei sheng yan jiu = Journal of hygiene research, 2011, Volume: 40, Issue:2

    Topics: Adenine; Animals; Antioxidants; Blood Urea Nitrogen; Creatinine; Ethambutol; Hyperuricemia; Kidney D

2011
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.
    The Journal of infectious diseases, 2011, Jul-01, Volume: 204, Issue:1

    Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Kidney; Kidney Diseases; Kidney Tubules; M

2011
Determination of kidney function before tenofovir initiation: four-fold difference in need of tenofovir dose reduction depending on method used.
    Journal of acquired immune deficiency syndromes (1999), 2011, Jun-01, Volume: 57, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rat

2011
Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:2

    Topics: Adenine; Adolescent; Adult; Aged; Drug Administration Schedule; Drug Therapy, Combination; Female; G

2012
[The influence of suoquan capsule on the mRNA expression of CYP11B2 in deficiency of the kidney and diuresis rats].
    Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, 2011, Volume: 34, Issue:1

    Topics: Adenine; Aldosterone; Animals; Corticosterone; Cytochrome P-450 CYP11B2; Disease Models, Animal; Diu

2011
Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2012, Volume: 18, Issue:2

    Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Drug Administration Schedule; Female; Glomerular

2012
Tenofovir induced acute kidney injury in a patient with unilateral renal agenesis despite initially non-impaired renal function.
    European journal of medical research, 2011, Dec-02, Volume: 16, Issue:12

    Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Congenital Abnormalities; HIV Infections; Huma

2011
Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
    AIDS patient care and STDs, 2012, Volume: 26, Issue:1

    Topics: Adenine; Anti-HIV Agents; Biomarkers; Cohort Studies; Cytochromes c; Deoxycytidine; Dideoxynucleosid

2012
Tenofovir-induced nephrotoxicity: myths and facts.
    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2012, Volume: 23, Issue:1

    Topics: Adenine; Animals; Anti-HIV Agents; Evidence-Based Medicine; HIV Infections; HIV-1; Humans; Kidney Di

2012
Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
    BMC infectious diseases, 2012, Jan-23, Volume: 12

    Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Female; HIV Infections; HIV Protease Inhibitors; Humans

2012
Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2012, Volume: 10, Issue:8

    Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Creatinine; Female; Glomerular Filtration Ra

2012
Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: a case-control study.
    Scandinavian journal of infectious diseases, 2012, Volume: 44, Issue:11

    Topics: Adenine; Adult; Aged; Case-Control Studies; CD4 Lymphocyte Count; Chi-Square Distribution; Deoxycyti

2012
High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy.
    Antiviral research, 2012, Volume: 96, Issue:1

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Kidney; Kidne

2012
Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55, Issue:11

    Topics: Adenine; Adult; Cohort Studies; Cross-Sectional Studies; Female; Genetic Predisposition to Disease;

2012
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
    Scandinavian journal of infectious diseases, 2013, Volume: 45, Issue:2

    Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabi

2013
Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:4

    Topics: Adenine; Adult; Anti-HIV Agents; Canada; Cohort Studies; Female; Follow-Up Studies; Glomerular Filtr

2013
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012, Volume: 26, Issue:12

    Topics: Adenine; Allied Health Personnel; Antibodies, Viral; Antiviral Agents; Canada; Coinfection; Drug Res

2012
A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013, Volume: 28, Issue:7

    Topics: Adenine; Anemia, Iron-Deficiency; Animals; Anti-Infective Agents; Blotting, Western; Bone Morphogene

2013
FDA recommends hepatitis B drug.
    AIDS patient care and STDs, 2002, Volume: 16, Issue:10

    Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Approval; Hepatitis B; Humans; Kidney

2002
The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, Volume: 40, Issue:6

    Topics: 5' Flanking Region; Adenine; Adult; Chemokine CCL2; Disease Progression; Female; Gene Expression Reg

2002
Adefovir (Hepsera) for chronic hepatitis B infection.
    The Medical letter on drugs and therapeutics, 2002, Dec-09, Volume: 44, Issue:1145

    Topics: Adenine; Administration, Oral; Controlled Clinical Trials as Topic; Creatinine; Drug Resistance, Vir

2002
Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.
    The American journal of the medical sciences, 2002, Volume: 324, Issue:6

    Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Chronic Disease; HIV Infections; Humans; Kidne

2002
Tenofovir disoproxil fumarate.
    Drugs, 2003, Volume: 63, Issue:15

    Topics: Adenine; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; HIV Infections; HIV-

2003
Angiotensinogen gene variation and renoprotective efficacy of renin-angiotensin system blockade in IgA nephropathy.
    Kidney international, 2003, Volume: 64, Issue:3

    Topics: Adenine; Adult; Alleles; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors;

2003
Inhibition of aminonucleoside renal lesions in rats adenine, adenosine triphosphate (ATP) and flavine adenine dinucleotide (FAD).
    Acta medica et biologica, 1963, Volume: 10

    Topics: Adenine; Adenine Nucleotides; Adenosine Triphosphate; Animals; Flavin-Adenine Dinucleotide; Kidney;

1963
[ON THE ADENINE NUCLEOTIDE CONTENT OF ERYTHROCYTES IN RENAL INSUFFICIENCY].
    Klinische Wochenschrift, 1964, Feb-01, Volume: 42

    Topics: Acidosis; Acute Kidney Injury; Adenine; Adenine Nucleotides; Erythrocytes; Humans; Kidney Diseases;

1964
[Inhibition of aminonucleoside renal lesions in rats by adenine, adenosine triphosphate (ATP) and flavine adenine dinucleotide (FAD)].
    Japanese journal of medical science & biology, 1962, Apr-10, Volume: 51

    Topics: Adenine; Adenine Nucleotides; Adenosine Triphosphate; Animals; Coenzymes; Flavin-Adenine Dinucleotid

1962
Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine?
    Journal of acquired immune deficiency syndromes (1999), 2004, Apr-01, Volume: 35, Issue:4

    Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Didanosine; Drug Interactions; Drug Therapy, Combinatio

2004
Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity?
    AIDS (London, England), 2004, Aug-20, Volume: 18, Issue:12

    Topics: Adenine; Adult; Anti-HIV Agents; DNA, Mitochondrial; HIV Infections; HIV-1; Humans; Kidney Diseases;

2004
Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure.
    The American journal of medicine, 2004, Aug-15, Volume: 117, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Fanconi Syndrome; Humans; Kidne

2004
Dietary fiber suppresses elevation of uric acid and urea nitrogen concentrations in serum of rats with renal dysfunction induced by dietary adenine.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 2004, Volume: 74, Issue:4

    Topics: Adenine; Animals; Blood Urea Nitrogen; Cellulose; Chitin; Chitosan; Creatinine; Diet; Dietary Fiber;

2004
Antiretroviral therapy with tenofovir is associated with mild renal dysfunction.
    AIDS (London, England), 2005, Jan-03, Volume: 19, Issue:1

    Topics: Adenine; Anti-HIV Agents; Creatinine; Cross-Sectional Studies; Cystatin C; Cystatins; Glomerular Fil

2005
Tenofovir and renal toxicity.
    AIDS patient care and STDs, 2004, Volume: 18, Issue:10

    Topics: Adenine; Anti-HIV Agents; Creatinine; Humans; Kidney Diseases; Organophosphonates; Tenofovir; Viral

2004
Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study.
    HIV medicine, 2005, Volume: 6, Issue:4

    Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Female; HIV Infections; Humans; Hypophosphatemia; Kidne

2005
Tenofovir and changes in renal function.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Aug-15, Volume: 41, Issue:4

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Kidney Dise

2005
Progression of renal impairment under therapy with tenofovir.
    AIDS (London, England), 2005, Aug-12, Volume: 19, Issue:12

    Topics: Adenine; Anti-HIV Agents; Case-Control Studies; Disease Progression; Glomerular Filtration Rate; HIV

2005
Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study.
    AIDS patient care and STDs, 2005, Volume: 19, Issue:7

    Topics: Adenine; Antiretroviral Therapy, Highly Active; Case-Control Studies; Creatinine; Dose-Response Rela

2005
Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.
    Pediatric nephrology (Berlin, Germany), 2006, Volume: 21, Issue:7

    Topics: Adenine; Anti-HIV Agents; Child; Diabetes Insipidus, Nephrogenic; Didanosine; Drug Therapy, Combinat

2006
Hypokalemia in HIV patients on tenofovir.
    AIDS (London, England), 2006, Aug-01, Volume: 20, Issue:12

    Topics: Adenine; Adolescent; Adult; Body Weight; Child; Didanosine; Drug Therapy, Combination; Female; HIV I

2006
Estimating renal function in patients on tenofovir disoproxil fumarate: suggestions for safer use.
    HIV medicine, 2006, Volume: 7, Issue:7

    Topics: Adenine; Creatinine; Dose-Response Relationship, Drug; Fanconi Syndrome; Glomerular Filtration Rate;

2006
HIV-associated nephropathy and drug-induced renal injury.
    MedGenMed : Medscape general medicine, 2006, Jun-08, Volume: 8, Issue:2

    Topics: Adenine; AIDS-Associated Nephropathy; Anti-HIV Agents; Humans; Kidney Diseases; Male; Middle Aged; O

2006
[Affection of Bushen Shengjing pill on NO and NOS in testicle and ante-oxidization of rat with spermatogenic cell injury].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2006, Volume: 31, Issue:11

    Topics: Adenine; Animals; Drug Combinations; Drugs, Chinese Herbal; Fertility Agents, Male; Kidney Diseases;

2006
Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2007, Volume: 13, Issue:3

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; H

2007
Editorial comment: tenofovir-related nephrotoxicity--who's at risk?
    The AIDS reader, 2007, Volume: 17, Issue:2

    Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans

2007
Tenofovir-induced kidney injury.
    Expert opinion on drug safety, 2007, Volume: 6, Issue:2

    Topics: Adenine; Animals; Anti-HIV Agents; Humans; Kidney Diseases; Organophosphonates; Tenofovir

2007
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
    AIDS (London, England), 2007, Jun-19, Volume: 21, Issue:10

    Topics: Adenine; Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Anti-Retroviral Agents; Antivi

2007
Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2008, Volume: 62, Issue:1

    Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Cohort Studies; Comorbidity; Female; Follow-Up Studies

2008
Effect of tenofovir on renal glomerular and tubular function.
    AIDS (London, England), 2007, Jul-11, Volume: 21, Issue:11

    Topics: Adenine; Anti-Retroviral Agents; Case-Control Studies; Cross-Sectional Studies; Glomerular Filtratio

2007
A novel mutation of COL4A3 presents a different contribution to Alport syndrome and thin basement membrane nephropathy.
    American journal of nephrology, 2007, Volume: 27, Issue:5

    Topics: Adenine; Adult; Aged; Asian People; Aspartic Acid; Autoantigens; Base Sequence; Collagen Type IV; Co

2007
Is phosphatemia the best tool to monitor renal tenofovir toxicity?
    Journal of acquired immune deficiency syndromes (1999), 2007, Oct-01, Volume: 46, Issue:2

    Topics: Adenine; Biomarkers; Creatinine; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases

2007
Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context.
    The Journal of infectious diseases, 2008, Jan-01, Volume: 197, Issue:1

    Topics: Adenine; HIV Infections; Humans; Kidney Diseases; Kidney Tubules; Organophosphonates; Reverse Transc

2008
Association between genetic variation in transforming growth factors beta1 and beta3 and renal dysfunction in non-diabetic Chinese.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2008, Volume: 30, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Albuminuria; Asian People; Creatinine; Cytosine; Female; Ge

2008
[Change of aquaporin-1 in rat models of kidney-yang-deficiency syndrome].
    Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2008, Volume: 6, Issue:5

    Topics: Adenine; Animals; Aquaporin 1; Diagnosis, Differential; Disease Models, Animal; Hydrocortisone; Kidn

2008
The prophylactic use of an "elemental" diet in experimental hemorrhagic shock and intestinal ischemia.
    Annals of surgery, 1967, Volume: 166, Issue:3

    Topics: Adenine; Adenosine Triphosphate; Animals; Blood Pressure; Chromatography; Digestion; Dogs; Epitheliu

1967
Uric acid crystal-induced nephropathy: evidence for a specific renal lesion in a gouty family.
    The Journal of pathology, 1981, Volume: 135, Issue:2

    Topics: Adenine; Adult; Animals; Child; Child, Preschool; Female; Gout; Humans; Kidney; Kidney Diseases; Swi

1981
Nephrotoxicity induced by adenine and its analogs: relationship between structure and renal injury.
    Biological & pharmaceutical bulletin, 1994, Volume: 17, Issue:8

    Topics: Adenine; Animals; Blood Urea Nitrogen; Creatinine; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred

1994
Enhanced neoplastic lesion development with adenine-induced experimental multicystic nephropathy by adenine--a model system for the analysis of renal tumor generation in long-term hemodialysis patients.
    Cancer letters, 1994, Aug-15, Volume: 83, Issue:1-2

    Topics: Adenine; Adenoma; Animals; Diethylnitrosamine; Epithelium; Hyperplasia; Kidney Diseases; Kidney Neop

1994
Effects of rhubarb tannins on renal function in rats with renal failure.
    Nihon Jinzo Gakkai shi, 1993, Volume: 35, Issue:1

    Topics: Adenine; Animals; Biflavonoids; Catechin; Glomerular Filtration Rate; Kidney; Kidney Diseases; Male;

1993
Fourier transform infrared microscopy identification of crystal deposits in tissues: clinical importance in various pathologies.
    American journal of clinical pathology, 1996, Volume: 105, Issue:5

    Topics: Adenine; Adult; Aged; Apatites; Biopsy; Calcium Phosphates; Child, Preschool; Crystallization; Femal

1996
New drugs in development.
    Project Inform perspective, 1998, Issue:25

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials a

1998
FDA panel fails to recommend adefovir approval. Food and Drug Administration.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1999, Volume: 12, Issue:4

    Topics: Adenine; Anti-HIV Agents; Drug Approval; HIV Infections; Humans; Kidney Diseases; Salvage Therapy; U

1999
[Hyperuricemia and gout--diagnosis].
    Deutsche medizinische Wochenschrift (1946), 2002, Feb-01, Volume: 127, Issue:5

    Topics: Adenine; Adult; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Female; Go

2002
Effects of dietary protein, adenine, and allopurinol on growth and metabolism of rats.
    The Journal of nutrition, 1977, Volume: 107, Issue:6

    Topics: Adenine; Allopurinol; Animals; Body Weight; Caseins; Dietary Proteins; Kidney; Kidney Diseases; Kidn

1977
Production of methylguanidine from creatinine in normal rats and rats with renal failure.
    Nephron, 1990, Volume: 56, Issue:3

    Topics: Adenine; Animals; Creatinine; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Kidney;

1990
[Enzymopathic gout. Dyspurinia due to hypoxanthine-guanine-phosphoribosyl-transferase deficiency. Occurrence and clinical characteristics of enzyme repression].
    La Presse medicale, 1970, Mar-28, Volume: 78, Issue:16

    Topics: Adenine; Adult; Age Factors; Allopurinol; Enzyme Repression; Female; Gout; Guanine; Humans; Hypoxant

1970
Attempts to alter kidney calcification in the magnesium-deficient rat.
    The Journal of nutrition, 1971, Volume: 101, Issue:1

    Topics: Adenine; Adenosine Triphosphate; Animals; Body Weight; Brain; Calcinosis; Diet; Dinitrophenols; Ethi

1971